Klotho Neurosciences (NASDAQ:KLTO) Trading 7.4% Higher – Here’s Why

Klotho Neurosciences, Inc. (NASDAQ:KLTO)’s share price traded up 7.4% on Tuesday . The company traded as high as $0.54 and last traded at $0.54. 2,014,213 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 2,565,419 shares. The stock had previously closed at $0.50.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Klotho Neurosciences to a “sell” rating in a research report on Saturday, July 5th.

Klotho Neurosciences Stock Performance

The business’s fifty day moving average is $0.96 and its two-hundred day moving average is $0.62. The company has a market cap of $33.01 million, a P/E ratio of -1.20 and a beta of 10.78.

Klotho Neurosciences (NASDAQ:KLTO) last announced its quarterly earnings data on Monday, August 18th. The company reported ($0.12) earnings per share for the quarter.

Institutional Investors Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC purchased a new stake in Klotho Neurosciences, Inc. (NASDAQ:KLTO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences as of its most recent filing with the SEC. Institutional investors and hedge funds own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.